Mawe GM, Hoffman JM
These pathways include BCL-XL, the cell cycle inhibitor p21, the ephrins EFNB1 and EFNB3, serpin PAI1, the oxygen sensor HIF-1 and phosphatidylinositol 3-kinase-delta (PI3K)
Although large cardiovascular outcome trials have consistently shown that GLP-1 RAs, particularly semaglutide and liraglutide, reduce all-cause death in people with type 2 diabetes [9, 10], these studies did not formally stratify death outcomes by age group, limiting direct comparisons with our findings
(PubMed) Olsen RK, Olpin SE, Andresen BS, et al
The two outcomes compound in a way that makes the effort and cost of running both compounds worthwhile compared to running either alone